Impact of Delayed Adoption of Novel Atrial Fibrillation Treatments

From the insurer's perspective, new treatment introduction requires a process of coverage decision-making, decisions on access restrictions such as prior authorization and step edits, decisions on co-pays and updates to coding/billing systems, and time needed for medical societies to update cli...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of managed care 2024-12
Main Author: Kim, Jaehong
Format: Article
Language:English
Subjects:
Anticoagulants
Cardiac arrhythmia
Case studies
Codes
Cohort analysis
Cost control
Cross-sectional studies
Disease
Expenditures
Geography
Health maintenance organizations
Health services utilization
HMOs
Ischemia
Medicare
Mortality
Patients
Stroke
Variables
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:From the insurer's perspective, new treatment introduction requires a process of coverage decision-making, decisions on access restrictions such as prior authorization and step edits, decisions on co-pays and updates to coding/billing systems, and time needed for medical societies to update clinical guidelines.5,6 Lack of physician awareness of new treatments also could contribute to adoption delays.7,8 Finally, physicians' persistence in treatment choice due to familiarity and experience could delay new treatments from becoming broadly adopted by patients.9 However, previous research has shown that treatment delays worsen health outcomes for certain diseases (eg, cystic fibrosis, cancer).10,11 Against this backdrop, this study explored the clinical and economic impacts of adoption delays in novel medical treatment using direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (NVAF) as a case study. [...]the impact of DOAC adoption rates on ischemic stroke outcomes in MSA- and individual-level regression analyses were evaluated. [...]we extrapolated regression results to identify the hypothetical impact of patients moving from a geographic region with slow (10th percentile) to rapid (90th percentile) DOAC adoption. Demographic control variables included patient age, sex, and insurance type (commercial health maintenance organization, preferred provider organization, point-of-service, or fee-for-service vs Medicare Advantage).
ISSN:1088-0224
1936-2692